MedTrace Logo

Drug-drug Interaction Study of FYU-981 and Oxaprozin

NCT03350386 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2022-09-14

No results posted yet for this study

Summary

This is an open-label, 2-period add-on study to assess the drug-drug interaction between FYU-981 and oxaprozin. The purpose of this study is to investigate the pharmacokinetics of each period in a single administration of FYU-981 and concomitant administration of FYU-981 with oxaprozin at steady -state in healthy volunteers.

Conditions

  • Healthy

Interventions

DRUG

FYU-981

Single administration

DRUG

Oxaprozin

Repeated administration

Sponsors & Collaborators

  • Fuji Yakuhin Co., Ltd.

    collaborator INDUSTRY

  • Mochida Pharmaceutical Company, Ltd.

    lead INDUSTRY

Principal Investigators

  • Nagasawa Katsuaki · Clinical Research Department

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-02
Primary Completion
2017-12-05
Completion
2017-12-05

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03350386 on ClinicalTrials.gov